<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vtio</journal-id><journal-title-group><journal-title xml:lang="ru">Вестник трансплантологии и искусственных органов</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Transplantology and Artificial Organs</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-1191</issn><publisher><publisher-name>Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15825/1995-1191-2024-2-82-93</article-id><article-id custom-type="elpub" pub-id-type="custom">vtio-1734</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Заместительная почечная терапия</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CARDIOVASCULAR ASPECTS OF TRANSPLANT SURGERY</subject></subj-group></article-categories><title-group><article-title>Гиперпаратиреоз у кандидатов  на трансплантацию почки и функция  околощитовидных желез у реципиентов в ранние  сроки послеоперационного периода</article-title><trans-title-group xml:lang="en"><trans-title>Hyperparathyroidism in kidney transplant  candidates and postoperative parathyroid gland  function in recipients</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ветчинникова</surname><given-names>О. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Vetchinnikova</surname><given-names>O. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ветчинникова Ольга Николаевна</p><p>129110, Москва, ул. Щепкина, 61/2</p><p>Тел. (916) 532-49-00</p></bio><bio xml:lang="en"><p>Olga Vetchinnikova</p><p>61/2, Shchepkina str., Moscow, 129110</p><p>Phone: (916) 532-49-00</p></bio><email xlink:type="simple">olg-vetchinnikova@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБУЗ МО «Московский областной научно-исследовательский клинический институт имени М.Ф. Владимирского»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Vladimirsky Moscow Regional Research and Clinical Institute</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>07</day><month>02</month><year>2024</year></pub-date><volume>26</volume><issue>2</issue><fpage>82</fpage><lpage>93</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ветчинникова О.Н., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Ветчинникова О.Н.</copyright-holder><copyright-holder xml:lang="en">Vetchinnikova O.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.transpl.ru/vtio/article/view/1734">https://journal.transpl.ru/vtio/article/view/1734</self-uri><abstract><sec><title>Цель</title><p>Цель: оценить влияние вторичного гиперпаратиреоза (ГПТ) у пациентов-кандидатов, ожидающих трансплантацию почки, на функцию околощитовидных желез реципиентов в течение первого послеоперационного года.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В ретроспективное когортное исследование включены 210 пациентов (103 женщины, 107 мужчин, возраст 45 ± 9 лет) с хронической болезнью почек 5–5 (Д) ст., перенесших трансплантацию трупной почки. Биохимическое исследование до трансплантации почки и в послеоперационном периоде через 3 и 12 мес. включало определение сывороточных концентраций паратиреоидного гормона (ПТГ), кальция, фосфора, активности щелочной фосфатазы, альбумина и креатинина стандартными методиками. Концентрации ПТГ крови 130–595 пг/мл и ≤130 пг/мл были приняты за целевой уровень соответственно в пред- и посттрансплантационном периоде.</p></sec><sec><title>Результаты</title><p>Результаты. ГПТ имели 56 (1-я группа), целевой уровень ПТГ крови – 154 (2-я группа) кандидата на трансплантацию почки. ПТГ крови составил соответственно 897 (722; 1136) и 301 (229; 411) пг/мл, р &lt; 0,001. Через 3 мес. после трансплантации почки ПТГ крови снизился у всех реципиентов: в 1-й группе на 595 (420; 812), во 2-й – на 148 (77; 230) пг/мл, р &lt; 0,001, и составил соответственно 254 (180; 455) и 150 (118; 212) пг/мл, р &lt; 0,001; целевой уровень определялся соответственно у 10,7 и 42,2% реципиентов, р &lt; 0,001. Через 12 мес. ПТГ крови составил в 1-й группе 171 (94; 239) пг/мл, во 2-й – 112 (90; 135) пг/мл, р = 0,004, целевой уровень определялся соответственно у 48,2 и 73,4% реципиентов, р &lt; 0,001. Функция почечного трансплантата была идентичной в обеих группах реципиентов: острый канальцевый некроз у 41,1 и 54,5%, через 3 мес. медиана скорости клубочковой фильтрации 60 и 65 мл/мин (н. д.), через 12 мес. – 56 и 54 мл/мин (н. д.). Посттрансплантационный ПТГ крови находился в прямой корреляционной зависимости от предоперационного в обеих группах и в обратной – с функцией почечного трансплантата у реципиентов 2-й группы.</p></sec><sec><title>Заключение</title><p>Заключение. ГПТ у кандидатов на трансплантацию почки является главным, не зависящим от функции трансплантата предиктором избыточной секреции ПТГ у реципиентов, увеличивая риск персистенции ГПТ в 1,9 раза через год после трансплантации почки.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Objective</title><p>Objective: to evaluate the effects of secondary hyperparathyroidism (HPT) in kidney transplantation (KT) candidates on recipients’ parathyroid gland function in the first postoperative year.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The retrospective cohort study included 210 patients (103 women, 107 men, age 45 ± 9 years) with stage 5 chronic kidney disease (stage 5 CKD, including dialysis-dependent patients), who had undergone cadaveric KT. Biochemical screening before kidney transplantation and in the postoperative period at 3 and 12 months determined serum levels of parathyroid hormone (PTH), calcium, phosphorus, alkaline phosphatase activity, albumin and creatinine using standard methods. PTH levels of 130–595 pg/mL and ≤130 pg/mL were taken as the target level in the pre- and post-transplant periods, respectively.</p></sec><sec><title>Results</title><p>Results. Fifty-six KT candidates (group 1) had HPT and 154 (group 2) had the target PTH levels. PTH level was 897 (722; 1136) and 301 (229; 411) pg/mL, respectively, p &lt; 0.001. PTH decreased in all recipients at 3 months after KT: by 595 (420; 812) in group 1 and 148 (77; 230) pg/ mL in group 2, p &lt; 0.001, to 254 (180; 455) and 150 (118; 212) pg/mL, respectively, p &lt; 0.001; the target level was detected in 10.7% and 42.2% of recipients, respectively, p &lt; 0.001. At 12 months, blood PTH was 171 (94; 239) pg/mL in group 1 and 112 (90; 135) pg/mL in group 2, p = 0.004; target level was found in 48.2% and 73.4% of recipients, respectively, p &lt; 0.001. Kidney graft function was identical in both recipient groups: acute tubular necrosis in 41.1% and 54.5%; at 3 months, median glomerular filtration rates (GFR) of 60 and 65 mL/min (n.d.); at 12 months, 56 and 54 mL/min (n.d.). Post-transplant PTH levels correlated directly with preoperative levels in both groups and inversely with renal graft function in group 2 recipients.</p></sec><sec><title>Conclusion</title><p>Conclusion. HPT in kidney transplant candidates is a major, graft function-independent predictor of excess PTH secretion in recipients, increasing the risk of persistent HPT 1.9-fold, one year after KT.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>трансплантация почки</kwd><kwd>околощитовидные железы</kwd><kwd>вторичный гиперпаратиреоз</kwd><kwd>хроническая болезнь почек</kwd></kwd-group><kwd-group xml:lang="en"><kwd>kidney transplantation</kwd><kwd>parathyroid glands</kwd><kwd>secondary hyperparathyroidism</kwd><kwd>chronic kidney</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Messa P, Alfieri CM. Secondary and tertiary hyperparathyroidism. Brandi ML (ed): Parathyroid Disorders. Focusing on Unmet Needs. Front Horm Res. 2019; 51: 91–108. doi: 10.1159/000491041.</mixed-citation><mixed-citation xml:lang="en">Messa P, Alfieri CM. Secondary and tertiary hyperparathyroidism. Brandi ML (ed): Parathyroid Disorders. Focusing on Unmet Needs. Front Horm Res. 2019; 51: 91–108. doi: 10.1159/000491041.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ветчинникова ОН. Гиперпаратиреоз и хроническая болезнь почек. Часть 1. Особенности патогенеза, клинические проявления, диагностическая стратегия. Лекция. Нефрология и диализ. 2023; 25 (1): 36–56. doi: 10.28996/26189801-2023-1-36-56.</mixed-citation><mixed-citation xml:lang="en">Vetchinnikova ON. Hyperparathyroidism and chronic kidney disease. Part 1. Features of pathogenesis, clinical manifestations, diagnostic strategy. Lecture. Nephrologу and Dialуsis. 2023; 25 (1): 36–56. doi: 10.28996/26189801-2023-1-36-56.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ермоленко ВМ, Волгина ГВ, Михайлова НА, Земченков АЮ, Ряснянский ВЮ, Ветчинникова ОН и др. Лечение минеральных и костных нарушений при хронической болезни почек. Нефрология. Клинические рекомендации. Под ред. Е.М. Шилова, А.В. Смирнова, Н.Л. Козловской. М.: ГЭОТАР-Медиа, 2016: 687–709.</mixed-citation><mixed-citation xml:lang="en">Ermolenko VM, Volgina GV, Mikhaylova NA, Zemchenkov AYu, Ryasnyanskiy VYu, Vetchinnikova ON i dr. Lechenie mineral’nykh i kostnykh narusheniy pri khronicheskoy bolezni pochek. Nefrologiya. Klinicheskie rekomendatsii. Pod red. E.M. Shilova, A.V. Smirnova, N.L. Kozlovskoy. M.: GEOTAR-Media, 2016: 687–709. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Alfieri C, Regalia A, Zanoni F, Vettoretti S, Cozzolino M, Messa P. The importance of adherence in the treatment of secondary hyperparathyroidism. Blood Purif. 2019; 47 (1-3): 37–44. doi: 10.1159/000492918.</mixed-citation><mixed-citation xml:lang="en">Alfieri C, Regalia A, Zanoni F, Vettoretti S, Cozzolino M, Messa P. The importance of adherence in the treatment of secondary hyperparathyroidism. Blood Purif. 2019; 47 (1-3): 37–44. doi: 10.1159/000492918.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ketteler M, Bover J, Mazzaferro S. Treatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022s. Nephrol Dial Transplant 2022; 0: 1–7. doi: 10.1093/ndt/gfac236.</mixed-citation><mixed-citation xml:lang="en">Ketteler M, Bover J, Mazzaferro S. Treatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022s. Nephrol Dial Transplant 2022; 0: 1–7. doi: 10.1093/ndt/gfac236.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Готье СВ, Хомяков СМ. Донорство и трансплантация органов в Российской Федерации в 2022 году. XV сообщение регистра Российского трансплантологического общества. Вестник трансплантологии и искусственных органов. 2023; ХХV (3): 8–30. doi: 10.15825/1995-1191-2023-3-8-30.</mixed-citation><mixed-citation xml:lang="en">Gautier SV, Khomyakov SM. Organ donation and transplantation in the Russian Federation in 2022. 15th Report from the Registry of the Russian Transplant Society. Russian Journal of Transplantology and Artificial Organs. 2023; ХХV (3): 8–30. (In Russ., English abstract). doi: 10.15825/1995-1191-2023-3-8-30.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Molinari P, Regalia A, Leoni A, Campise M, Cresseri D, Cicero E et al. Impact of hyperparathyroidism and its different subtypes on long term graft outcome: a single Transplant Center cohort study. Front Med (Lausanne). 2023; 10: 1221086. doi: 10.3389/fmed.2023.1221086.</mixed-citation><mixed-citation xml:lang="en">Molinari P, Regalia A, Leoni A, Campise M, Cresseri D, Cicero E et al. Impact of hyperparathyroidism and its different subtypes on long term graft outcome: a single Transplant Center cohort study. Front Med (Lausanne). 2023; 10: 1221086. doi: 10.3389/fmed.2023.1221086.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Yamamoto T, Tominaga Y, Okada M, Hiramitsu T, Tsujita M, Goto N et al. Characteristics of persistent hyperparathyroidism after renal transplantation. World J Surg. 2016; 40 (3): 600–606. doi: 10.1007/s00268-0153314-z. PMID: 26546189.</mixed-citation><mixed-citation xml:lang="en">Yamamoto T, Tominaga Y, Okada M, Hiramitsu T, Tsujita M, Goto N et al. Characteristics of persistent hyperparathyroidism after renal transplantation. World J Surg. 2016; 40 (3): 600–606. doi: 10.1007/s00268-0153314-z. PMID: 26546189.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Lou I, Foley D, Odorico SK, Leverson G, Schneider DF, Sippel R et al. How well does renal transplantation cure hyperparathyroidism? Ann Surg. 2015; 262 (4): 653– 659. doi: 10.1097/SLA.0000000000001431.</mixed-citation><mixed-citation xml:lang="en">Lou I, Foley D, Odorico SK, Leverson G, Schneider DF, Sippel R et al. How well does renal transplantation cure hyperparathyroidism? Ann Surg. 2015; 262 (4): 653– 659. doi: 10.1097/SLA.0000000000001431.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Pihlstrøm H, Dahle DO, Mjoen G, Pilz S, Marz W, Abedini S et al. Increased risk of all-cause mortality and renal graft loss in stable renal transplant recipients with hyperparathyroidism. Transplantation. 2015; 99 (2): 351–359. doi: 10.1097/tp.0000000000000583.</mixed-citation><mixed-citation xml:lang="en">Pihlstrøm H, Dahle DO, Mjoen G, Pilz S, Marz W, Abedini S et al. Increased risk of all-cause mortality and renal graft loss in stable renal transplant recipients with hyperparathyroidism. Transplantation. 2015; 99 (2): 351–359. doi: 10.1097/tp.0000000000000583.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Okada M, Tominaga Y, Sato T, Tomosugi T, Futamura K, Hiramitsu T et al. Elevated parathyroid hormone one year after kidney transplantation is an independent risk factor for graft loss even without hypercalcemia. BMC Nephrol. 2022; 23: 212. doi: 10.1186/S12882-02202840-5.</mixed-citation><mixed-citation xml:lang="en">Okada M, Tominaga Y, Sato T, Tomosugi T, Futamura K, Hiramitsu T et al. Elevated parathyroid hormone one year after kidney transplantation is an independent risk factor for graft loss even without hypercalcemia. BMC Nephrol. 2022; 23: 212. doi: 10.1186/S12882-02202840-5.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">KDIGO 2017. Clinical Practice Guideline Update for the Diagnosis, Evalution, Prevention and Treatment of Chronic Kidney Disease – Mineral and Bone Disorder (CKD-MBD). Kidney Int. 2017; 7 (1): 1–59.</mixed-citation><mixed-citation xml:lang="en">KDIGO 2017. Clinical Practice Guideline Update for the Diagnosis, Evalution, Prevention and Treatment of Chronic Kidney Disease – Mineral and Bone Disorder (CKD-MBD). Kidney Int. 2017; 7 (1): 1–59.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Perrin P, Caillard S, Javier RM, Braun L, Heibel F, Borni-Duval C et al. Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. Am J Transplant. 2013; 13: 2653–2663. doi: 10.1111/ajt.12425.</mixed-citation><mixed-citation xml:lang="en">Perrin P, Caillard S, Javier RM, Braun L, Heibel F, Borni-Duval C et al. Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. Am J Transplant. 2013; 13: 2653–2663. doi: 10.1111/ajt.12425.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Bleskestad IH, Bergrem H, Leivestad T, Hartmann A, Gøransson LG. Parathyroid hormone and clinical outcome in kidney transplant patients with optimal transplant function. Clin Transplant. 2014; 28: 479–486. doi: 10.1111/ctr12341.</mixed-citation><mixed-citation xml:lang="en">Bleskestad IH, Bergrem H, Leivestad T, Hartmann A, Gøransson LG. Parathyroid hormone and clinical outcome in kidney transplant patients with optimal transplant function. Clin Transplant. 2014; 28: 479–486. doi: 10.1111/ctr12341.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B, Vanrenterghem Y. Natural history of parathyroid function and calcium metabolism after kidney transplantation: A single-centre study. Nephrol Dial Transplant. 2004; 19: 1281–1287. doi: 10.1093/ndt/gfh128.</mixed-citation><mixed-citation xml:lang="en">Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B, Vanrenterghem Y. Natural history of parathyroid function and calcium metabolism after kidney transplantation: A single-centre study. Nephrol Dial Transplant. 2004; 19: 1281–1287. doi: 10.1093/ndt/gfh128.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">National kidney foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis. 2003; 42 (Suppl. 3): S1–S202.</mixed-citation><mixed-citation xml:lang="en">National kidney foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis. 2003; 42 (Suppl. 3): S1–S202.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Wang R, Price G, Disharoon M, Stidham G, McLeod M-C, McMullin JL et al. Resolution of secondary hyperparathyroidism after kidney transplantation and the effect on graft survival. Ann Surg. 2023; 278 (3): 366–375. doi: 10.1097/SLA.0000000000005946.</mixed-citation><mixed-citation xml:lang="en">Wang R, Price G, Disharoon M, Stidham G, McLeod M-C, McMullin JL et al. Resolution of secondary hyperparathyroidism after kidney transplantation and the effect on graft survival. Ann Surg. 2023; 278 (3): 366–375. doi: 10.1097/SLA.0000000000005946.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Sutton W, Chen X, Patel P, Karzai S, Prescott JD, Segev DL et al. Prevalence and risk factors for tertiary hyperparathyroidism in kidney transplant recipients. Surgery. 2022; 171 (1): 69–76. doi: 10.1016/j.surg.2021.03.067.</mixed-citation><mixed-citation xml:lang="en">Sutton W, Chen X, Patel P, Karzai S, Prescott JD, Segev DL et al. Prevalence and risk factors for tertiary hyperparathyroidism in kidney transplant recipients. Surgery. 2022; 171 (1): 69–76. doi: 10.1016/j.surg.2021.03.067.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Okada M, Sato T, Hasegawa Y, Futamura K, Hiramitsu T, Ichimori T et al. Persistent hyperparathyroidism after preemptive kidney transplantation. Clin Exp Nephrol. 2023; Jun 23. doi: 10.1007/s10157-023-02371-9.</mixed-citation><mixed-citation xml:lang="en">Okada M, Sato T, Hasegawa Y, Futamura K, Hiramitsu T, Ichimori T et al. Persistent hyperparathyroidism after preemptive kidney transplantation. Clin Exp Nephrol. 2023; Jun 23. doi: 10.1007/s10157-023-02371-9.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kirnap NG, Kirnap M, Sayin B, Akdur A, Bascil Tutuncu N, Haberal M. Risk factors and treatment options for persistent hyperparathyroidism after kidney transplantation. Transplant Proc. 2020; 52 (1): 157–161. doi: 10.1016/j.transproceed.2019.11.020.</mixed-citation><mixed-citation xml:lang="en">Kirnap NG, Kirnap M, Sayin B, Akdur A, Bascil Tutuncu N, Haberal M. Risk factors and treatment options for persistent hyperparathyroidism after kidney transplantation. Transplant Proc. 2020; 52 (1): 157–161. doi: 10.1016/j.transproceed.2019.11.020.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Chadban SJ, Ahn C, Axelrod DA, Foster BJ, Kasiske BL, Kher V et al. KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation. Transplantation. 2020; 104 (4S1 Suppl. 1): S11–S103. doi: 10.1097/TP.0000000000003136. PMID: 32301874.</mixed-citation><mixed-citation xml:lang="en">Chadban SJ, Ahn C, Axelrod DA, Foster BJ, Kasiske BL, Kher V et al. KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation. Transplantation. 2020; 104 (4S1 Suppl. 1): S11–S103. doi: 10.1097/TP.0000000000003136. PMID: 32301874.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Puttarajappa CM, Schinstock CA, Wu CM, Leca N, Kumar V, Vasudev BS, Hariharan S. KDOQI US commentary on the 2020 KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation. Am J Kidney Dis. 2021; 77 (6): 833–856. doi: 10.1053/j.ajkd.2020.11.017.</mixed-citation><mixed-citation xml:lang="en">Puttarajappa CM, Schinstock CA, Wu CM, Leca N, Kumar V, Vasudev BS, Hariharan S. KDOQI US commentary on the 2020 KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation. Am J Kidney Dis. 2021; 77 (6): 833–856. doi: 10.1053/j.ajkd.2020.11.017.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Смирнов АВ, Ватазин АВ, Добронравов ВА, Бобкова ИН, Ветчинникова ОН, Волгина ГВ и др. Клинические рекомендации. Хроническая болезнь почек (ХБП). Нефрология. 2021; 25 (5): 10–84. doi: 10.36485/1561-6274-2021-25-5-10-84.</mixed-citation><mixed-citation xml:lang="en">Smirnov AV, Vatazin AV, Dobronravov VA, Bobkova IN, Vetchinnikova ON, Volgina GV et al. Clinical recommendations. Chronic kidney disease (CKD). Nephrology (SaintPetersburg). 2021; 25 (5): 10–84. (In Russ.). doi: 10.36485/1561-6274-2021-25-5-10-84.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Egan CE, Qazi M, Lee J, Lee-Saxton YJ, Greenberg JA, Beninato T et al. Treatment of secondary hyperparathyroidism and posttransplant tertiary hyperparathyroidism. J Surg Res. 2023; 291: 330–335. doi: 10.1016/j.jss.2023.06.031.</mixed-citation><mixed-citation xml:lang="en">Egan CE, Qazi M, Lee J, Lee-Saxton YJ, Greenberg JA, Beninato T et al. Treatment of secondary hyperparathyroidism and posttransplant tertiary hyperparathyroidism. J Surg Res. 2023; 291: 330–335. doi: 10.1016/j.jss.2023.06.031.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Jeon HJ, Kim YJ, Kwon HY, Koo TY, Baek SH, Kim HJ et al. Impact of parathyroidectomy on allograft outcomes in kidney transplantation. Transpl Int. 2012; 25 (12): 1248–1256. doi: 10.1111/j.1432-2277.2012.01564.x.</mixed-citation><mixed-citation xml:lang="en">Jeon HJ, Kim YJ, Kwon HY, Koo TY, Baek SH, Kim HJ et al. Impact of parathyroidectomy on allograft outcomes in kidney transplantation. Transpl Int. 2012; 25 (12): 1248–1256. doi: 10.1111/j.1432-2277.2012.01564.x.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Littbarski SA, Kaltenborn A, Gwiasda J, Beneke J, Arelin V, Schwager Y et al. Timing of parathyroidectomy in kidney transplant candidates with secondary hyperparathryroidism: Effect of pretransplant versus early or late post-transplant parathyroidectomy. Surgery. 2018; 163 (2): 373–380. doi: 10.1016/j.surg.2017.10.016.</mixed-citation><mixed-citation xml:lang="en">Littbarski SA, Kaltenborn A, Gwiasda J, Beneke J, Arelin V, Schwager Y et al. Timing of parathyroidectomy in kidney transplant candidates with secondary hyperparathryroidism: Effect of pretransplant versus early or late post-transplant parathyroidectomy. Surgery. 2018; 163 (2): 373–380. doi: 10.1016/j.surg.2017.10.016.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Alagoz S, Trabulus S. Long-term evaluation of mineral metabolism after kidney transplantation. Transplant Proc. 2019; 51 (7): 2330–2333. doi: 10.1016/j.transproceed.2019.01.181.</mixed-citation><mixed-citation xml:lang="en">Alagoz S, Trabulus S. Long-term evaluation of mineral metabolism after kidney transplantation. Transplant Proc. 2019; 51 (7): 2330–2333. doi: 10.1016/j.transproceed.2019.01.181.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Kettler B, Scheffner I, Bräsen JH, Hallensleben M, Richter N, Heiringhoff KH et al. Kidney graft survival of &gt;25 years: a single center report including associated graft biopsy results. Transpl Int. 2019; 32 (12): 1277–1285. doi: 10.1111/tri.13469.</mixed-citation><mixed-citation xml:lang="en">Kettler B, Scheffner I, Bräsen JH, Hallensleben M, Richter N, Heiringhoff KH et al. Kidney graft survival of &gt;25 years: a single center report including associated graft biopsy results. Transpl Int. 2019; 32 (12): 1277–1285. doi: 10.1111/tri.13469.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Araujo MJCLN, Ramalho JAM, Elias RM, Jorgetti V, Nahas W, Custodio M et al. Persistent hyperparathyroidism as a risk factor for long-term graft failure: the need to discuss indication for parathyroidectomy. Surgery. 2018; 163: 1144–1150. doi: 10.1016/j.surg.2017.12.010.</mixed-citation><mixed-citation xml:lang="en">Araujo MJCLN, Ramalho JAM, Elias RM, Jorgetti V, Nahas W, Custodio M et al. Persistent hyperparathyroidism as a risk factor for long-term graft failure: the need to discuss indication for parathyroidectomy. Surgery. 2018; 163: 1144–1150. doi: 10.1016/j.surg.2017.12.010.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Isakov O, Ghinea R, Beckerman P, Mor E, Riella LV, Hod T. Early persistent hyperparathyroidism post-renal transplantation as a predictor of worse graft function and mortality after transplantation. Clin Transpl. 2020; 34:e14085. doi: 10.1111/ctr.14085.</mixed-citation><mixed-citation xml:lang="en">Isakov O, Ghinea R, Beckerman P, Mor E, Riella LV, Hod T. Early persistent hyperparathyroidism post-renal transplantation as a predictor of worse graft function and mortality after transplantation. Clin Transpl. 2020; 34:e14085. doi: 10.1111/ctr.14085.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Tsai M-H, Chen M, Liou H-H, Lee T-S, Huang Y-C, Liu P-Y, Fang Y-W. Impact of pre-transplant parathyroidectomy on graft survival: A comparative study of renal transplant patients (2005–2015). Med Sci Monit. 2023; 29:e940959. doi: 10.12659/MSM.940959.</mixed-citation><mixed-citation xml:lang="en">Tsai M-H, Chen M, Liou H-H, Lee T-S, Huang Y-C, Liu P-Y, Fang Y-W. Impact of pre-transplant parathyroidectomy on graft survival: A comparative study of renal transplant patients (2005–2015). Med Sci Monit. 2023; 29:e940959. doi: 10.12659/MSM.940959.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Massfelder T, Parekh N, Endlich K, Saussine C, Steinhausen M, Helwig JJ. Effect of intrarenally infused parathyroid hormone-related protein on renal blood flow and glomerular filtration rate in the anaesthetized. Br J Pharmacol. 1996; 118: 1995–2000. doi: 10.1111/j.14765381.1996.tb15635.x.</mixed-citation><mixed-citation xml:lang="en">Massfelder T, Parekh N, Endlich K, Saussine C, Steinhausen M, Helwig JJ. Effect of intrarenally infused parathyroid hormone-related protein on renal blood flow and glomerular filtration rate in the anaesthetized. Br J Pharmacol. 1996; 118: 1995–2000. doi: 10.1111/j.14765381.1996.tb15635.x.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Schwarz A, Rustien G, Merkel S, Radermacher J, Haller H. Decreased renal transplant function after parathyroidectomy. Nephrol Dial Transplant. 2007; 22: 584– 591. doi: 10.1093/ndt/gfl583.</mixed-citation><mixed-citation xml:lang="en">Schwarz A, Rustien G, Merkel S, Radermacher J, Haller H. Decreased renal transplant function after parathyroidectomy. Nephrol Dial Transplant. 2007; 22: 584– 591. doi: 10.1093/ndt/gfl583.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Ruda JM, Hollenbeak CS, Stack BC Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg. 2005; 132: 359–372. doi: 10.1016/j.otohns.2004.10.005.</mixed-citation><mixed-citation xml:lang="en">Ruda JM, Hollenbeak CS, Stack BC Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg. 2005; 132: 359–372. doi: 10.1016/j.otohns.2004.10.005.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Duque EJ, Elias RM, Moysés RMA. Parathyroid hormone: A uremic toxin. Toxins. 2020; 12: 189–204. doi: 10.3390/toxins12030189.</mixed-citation><mixed-citation xml:lang="en">Duque EJ, Elias RM, Moysés RMA. Parathyroid hormone: A uremic toxin. Toxins. 2020; 12: 189–204. doi: 10.3390/toxins12030189.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
